Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jul;16(4):371-381.
doi: 10.2450/2017.0354-16. Epub 2017 May 26.

Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis

Affiliations
Review

Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis

Piercarla Schinco et al. Blood Transfus. 2018 Jul.

Abstract

Recent advances in the care of von Willebrand's disease (vWD) have allowed the majority of patients to be managed adequately. Even in the more severe forms, it is now possible to control recurrent bleeding through secondary long-term prophylaxis with von Willebrand factor-containing concentrates. Moreover, in the setting of surgical prophylaxis, the combination of interdisciplinary management and close patient monitoring yields a positive outcome in nearly all cases, although safety concerns remain. In clinical practice, the effectiveness of therapy is hindered by the difficulties in making a rapid, yet accurate diagnosis, in identifying the subgroup of bleeders who may benefit most from a specific strategy, and in selecting the optimal product and regimen.Since specific guidelines for heavy bleeders requiring short- and long-term prophylaxis are still lacking, sharing the experience of experts dealing with vWD patients on a daily basis is crucial to fill gaps in information relating to patient management. To address this important issue, 13 Italian haematologists met in Milan on April, 2, 2016 and in Florence on July, 9, 2016. A 30-question survey constituted the input to discuss (i) optimisation of the diagnostic workflow for vWD, (ii) the characteristics of patients who may benefit from secondary long-term prophylaxis (in particular with the purified von Willebrand factor concentrate with a low content of factor VIII), (iii) the key elements to consider when selecting a concentrate and (iv) the pre-operative and post-operative management of vWD patients. A summary of the main points covered is provided in this report.

PubMed Disclaimer

Conflict of interest statement

Disclousure of conflict of interest

PS has received grants from Kedrion for her Institutional research activity. All participating experts in vWD, except for ACG, received the honorarium for both meetings of the working group. Moreover, PS has been involved in advisory boards and has received honoraria as a speaker at educational meetings organised by Bayer, Baxter/Shire, CSL Behring, Grifols, Kedrion Biopharma, NovoNordisk, Pfizer, and Sobi; GC has received fees for advisory board participation and as speaker for Bayer, Baxalta, NovoNordisk, CSL Behring, and SOBI; AC has received fees as an invited speaker or consultant from Bayer, CSL Behring, NovoNordisk, and Octapharma; DC has received fees as an invited speaker from Kedrion; CE has received fees as an invited speaker or consultant from Bayer, CSL Behring, NovoNordisk, Octapharma, and Baxalta; EM has received fees as a consultant or invited speaker from Bayer, Pfizer, and Kedrion; RM has received fees as a consultant or invited speaker from Bayer, NovoNordisk, and Shire; MM has received fees as a speaker or consultant from Sobi, Kedrion and Abbvie, and a research fellowship from Bayer; CM has received fees as a consultant or invited speaker from Bayer, CSL Behring, Kedrion, NovoNordisk, Pfizer, Shire, and Sobi; EZ has received fees as an invited speaker or consultant from Bayer, CSL Behring, NovoNordisk, Baxalta, and Kedrion; ABF has been involved in advisory boards and has received honoraria as a speaker at educational meetings organised by Baxter/Shire, CSL Behring, Grifols, Kedrion Biopharma, LFB, Octapharma, and Werfen-Instrumentation laboratories. SMS declares no additional conflicts of interest.

Comment in

References

    1. Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood. 2015;125:2029–37. - PMC - PubMed
    1. Castaman G, Federici AB, Tosetto A, et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost. 2012;10:632–8. - PubMed
    1. Federici AB, Bucciarelli P, Castaman G, et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood. 2014;123:4037–44. - PubMed
    1. Barr RD, Sek J, Horsman J, et al. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol. 2003;73:108–14. - PubMed
    1. de Wee EM, Mauser-Bunschoten EP, Van Der Bom JG, et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease. J Thromb Haemost. 2010;8:1492–9. - PubMed

MeSH terms